Holen Sie sich die Stockscreener-App
0.7806
0.41%
-0.0032
Handel nachbörslich:
.85
0.0694
+8.89%
Schlusskurs vom Vortag:
$0.7838
Offen:
$0.781
24-Stunden-Volumen:
99,900
Relative Volume:
0.22
Marktkapitalisierung:
$7.72M
Einnahmen:
$3.95M
Nettoeinkommen (Verlust:
$-14.59M
KGV:
-0.6714
EPS:
-1.1626
Netto-Cashflow:
$-14.46M
1W Leistung:
+6.23%
1M Leistung:
+1.68%
6M Leistung:
-37.55%
1J Leistung:
-34.40%
1-Tages-Spanne:
$0.77
$0.8334
1-Wochen-Bereich:
$0.7538
$0.8334
52-Wochen-Spanne:
$0.72
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.7806 | 7.75M | 3.95M | -14.59M | -14.46M | -1.1626 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-07-29 | Eingeleitet | Aegis Capital | Buy |
| 2020-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Eingeleitet | Oppenheimer | Outperform |
Evogene Ltd Aktie (EVGN) Neueste Nachrichten
Movement Recap: Can Evogene Ltd disrupt its industry2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Evogene receives Nasdaq notification - MSN
[EFFECT] Evogene Ltd. SEC Filing - Stock Titan
Evogene Ltd. (EVGN) stock price, news, quote and history - Yahoo Finance UK
Evogene receives Nasdaq delisting warning over share price By Investing.com - Investing.com Canada
Evogene reports receipt of Nasdaq minimum bid price notification - marketscreener.com
Evogene receives Nasdaq delisting warning over share price - Investing.com
Evogene Faces Nasdaq Minimum Bid Price Deficiency, Granted Cure Period to September 2026 - TipRanks
Evogene Gets Nasdaq Minimum Bid Price Notification - marketscreener.com
Nasdaq warns Evogene (NASDAQ: EVGN) over $1.00 minimum bid rule - Stock Titan
Nasdaq gives Evogene until Sept. 28 to fix its sub-$1 stock price - Stock Titan
Evogene stock soars after licensing deal for cancer therapeutic - Investing.com
Evogene Ltd Stock: Pioneering AI-Driven Plant Genomics for Sustainable Agriculture Markets - AD HOC NEWS
Casterra reports successful castor farming trials in Brazil By Investing.com - Investing.com South Africa
Evogene Ltd. (EVGN) Stock Price, News, Quote & History - Yahoo Finance
Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock - Finviz
Casterra reports successful castor farming trials in Brazil - Investing.com
Evogene files for resale of 5.08M shares via warrant exercise - MSN
Brazil field trials show castor oil can scale as a biofuel feedstock - Stock Titan
EVGN SEC FilingsEvogene 10-K, 10-Q, 8-K Forms - Stock Titan
Chipmakers Recap: Will Evogene Ltd stock hit new highs in YEAREarnings Miss & Smart Allocation Stock Tips - baoquankhu1.vn
Market Recap: Is Evogene Ltd stock a hidden gemCEO Change & Precise Buy Zone Tips - baoquankhu1.vn
Evogene (NASDAQ: EVGN) resale registration for 5.08M ordinary shares - Stock Titan
Armistice selling up to 2.45M Evogene shares (NASDAQ: EVGN) - Stock Titan
Evogene Ltd Stock Faces Pressure Amid Biotech Sector Volatility and Pipeline Delays in 2026 - AD HOC NEWS
Evogene Earnings Call: AI Ambition Meets Cash Reality - TipRanks
If You Invested $1,000 in Evogene (EVGN) - Stock Titan
Evogene appoints Dr. Olga Nissan as vice president of business development to drive AI-driven growth - MSN
EVGN PE Ratio & Valuation, Is EVGN Overvalued - Intellectia AI
Evogene (EVGN) director Leon Recanati details share and option holdings - Stock Titan
Evogene (EVGN) director Nir details multiple stock option grants in Form 3 - Stock Titan
Evogene (EVGN) director details stock option grants and vesting - Stock Titan
Evogene (EVGN) chief development officer reports 40,000-share stock option grant - Stock Titan
[Form 3] Evogene Ltd. Initial Statement of Beneficial Ownership - Stock Titan
Evogene (EVGN) director Sarit Firon details long-dated stock option grants - Stock Titan
Evogene (EVGN) CFO details RSU and stock option holdings - Stock Titan
Evogene (EVGN) CEO Haviv Ofer details multi-year stock option grants - Stock Titan
Evogene Ltd Stock (ISIN: IL0010831684) Faces Biotech Volatility Amid AI-Driven Crop Innovation Push - AD HOC NEWS
Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline By GuruFocus - Investing.com Canada
Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Evogene outlines ChemPass AI-driven strategy and anticipates new collaborations amid organizational realignment - MSN
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 - Sahm
Evogene Ltd. (NASDAQ:EVGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Evogene Financial Results: Quarterly and Annual ReportNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Evogene Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
Evogene: Q4 Earnings Snapshot - theheraldreview.com
Evogene earnings missed by $0.20, revenue topped estimates - Investing.com Australia
Evogene Q4 2025 Earnings Call Transcript - MarketBeat
Finanzdaten der Evogene Ltd-Aktie (EVGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):